Kemwell AB, the Sweden-based contract manufacturing and product development services arm of the family owned group of Kemwell Pvt Ltd, is investing around Euros 2 million for its second facility at Uppsala in Sweden. The dedicated contract manufacturer, Kemwell in India has plants at Bangalore and at Uppsala in Sweden. The latter was a Pfizer facility acquired by Kemwell in 2006.

The new unit will double the production capacity to cater orders for manufacturing pharmaceuticals for companies in the US, EU and Japanese markets. This year we will invest around Euros 2 million in the facility, but it will definitely be much larger amounts over the coming years towards equipment and personnel. The modern factory in Uppsala makes it possible to optimize future expansion. We see a bright outlook for the company’s development, said Agneta Bergvall, CEO, Kemwell AB told Pharmabiz in an email interaction.

Owing to strong company development, Kemwell has now decided to increase their production capacity by expanding the production area from 16,000 to 31,000 square meters. The expansion not only makes it possible for the company to increase production of tablets, suppositories and capsules but will also allow the company to expand into other product types, he added.

Our new pharmaceutical factory is a fully automated and flexible facility. It will also allow for production of other formulations. The company expects production in the new facility to start during 2010.

The new pharmaceutical factory in Uppsala gives us unique possibilities. We are very happy that our owners have chosen to expand in Sweden. Our employees have the experience and are highly competent in the area of large-scale production, said Bergvall.

Kemwell is today one of the largest pharmaceutical contract manufacturing companies in India and will as a result of this expansion capture a bigger chunk of market share in the European market too, she said.

The new facility is in accordance with the expansive stage of the company considering the discussions that are taking place with several international pharmaceutical companies. Now we can help our customers become even more competitive by assuming their need for full scale production. At the same time we are expanding our analytical and method development and stability studies as well as re-analysis of products for the EU market but manufactured outside EU (so called QP release), stated Leo Fällgren, manager, business development, Kemwell AB.